FDA Panel Backs Approval for Forest’s Ceftaroline

An FDA advisory committee has given unanimous approval to Forest Laboratories’ antibiotic ceftaroline for the treatment of community-acquired pneumonia (CAP) and complicated skin and skin structure infections (CSSI). The agency’s Anti-Infective Drugs Advisory Committee voted 21–0 to recommend ceftaroline for the treatment of CAP and 18–0 for the treatment of CSSI, with several panel members calling the vote an easy decision.
Washington Drug Letter